SCHEMBL149172

SCHEMBL149172

Cc1c(Br)cccc1NC(=O)c1ccccc1F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGER Q15109 1/20 0.53
TDP1 Q9NUW8 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
L3MBTL1 Q9Y468 3/20 0.52
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
TSHR P16473 2/20 0.51
HTT P42858 2/20 0.51
LMNA P02545 1/20 0.51
TP53 P04637 1/20 0.51
HSD17B10 Q99714 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
POLB P06746 1/20 0.50
MAPT P10636 1/20 0.50
GAA P10253 1/20 0.50
HPGD P15428 1/20 0.50
ATM Q13315 2/20 0.49
USP2 O75604 1/20 0.49
ALDH1A1 P00352 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26066354 0.88 TDP1 (0.59) AGERTDP1MEN1KMT2AL3MBTL1
SCHEMBL29782472 0.87 NPC1 (0.49) AGERMEN1KMT2ANPC1RAB9A
SCHEMBL16320407 0.87 NPC1 (0.49) AGERMEN1KMT2ANPC1RAB9A
SCHEMBL13098142 0.84 KMT2A (0.54) TDP1MEN1KMT2AL3MBTL1NPC1
SCHEMBL149041 0.82 ALDH1A1 (0.44) AGERMEN1KMT2AL3MBTL1NPC1
SCHEMBL16319974 0.82 NPC1 (0.72) MEN1KMT2ANPC1RAB9ATSHR
SCHEMBL29782428 0.82 NPC1 (0.72) MEN1KMT2ANPC1RAB9ATSHR
SCHEMBL17904699 0.82 NPC1 (0.61) MEN1KMT2ANPC1RAB9ATSHR
SCHEMBL30836634 0.80 KDM4E (0.43) MEN1KMT2ANPC1RAB9ATSHR
SCHEMBL30836826 0.80 PTGER4 (0.43) AGERMEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2391602-B1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2013-12-04 EP disclosed
US-8362065-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 US disclosed
EP-2391602-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-12-07 EP disclosed
WO-2010080481-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 AGER 4263/4885TDP1 1220/4885MEN1 3158/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 AGER 4263/4885TDP1 1220/4885MEN1 3158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.